Page 82 - Fisica In Medicina n° 1/2017

^Äëíê~Åí=jÉÇáÅá= =fractionation schemes were 40 Gy in 5 fractions and 35 Gy in 5 fractions. Overall Survival (OS), Cancer-Specific Survival (CSS), and Local Control (LC) were calculated from the end date of SBRT to the end of follow-up; Progression-Free Survival (PFS) was calculated from the end date of SBRT to the first clinical progression. Treatment related toxicity was evaluated using the CTCAE version 4.0.ResultsMedian follow-up was 22.68 months (range 1.9-95.73). One year and 2 years LC were 91% and 89%, respectively. Thirty-one patients (39.7%) were free from local and systemic progression: one and 2-year PFS were 85% and 72%, respectively. CSS at one year was 93% and it was 85% at two years. One and 2-year OS were 92% and 82%, respectively . At the univariate analysis, we found that KPS was a statistically significant prognostic factor for OS, PFS(p=0.00 for both) and CCS (p= 0.17). OS was also influenced by the primitive tumor (p=0.006). 8 (10.2%) patients developed acute toxicity >2, while 5 patients (6.4%) developed late toxicity >2.ConclusionSBRT is a safe and effective management option for the control of oligometastatic disease . This therapeutic approach can have an important role in delaying disease progression. Toxicity seems to be moderate in most cases.73